Search bioRxiv⌕ Search

Biology subjects

Jezova, D.

Publications and source records attributed to Jezova, D..

2 recordsLinked to original sources

Consequences of Early Postnatal Blockade of Aldosterone Synthesis on Behaviour and Stress Response in Male and Female Rats

AimThe aim of the present study was to determine whether pharmacological inhibition of aldosterone synthesis during the stress-hyporesponsive period (SHRP) affects behaviour and adrenocortical stress responsiveness later in development and whether these effects differ between males and females. MethodsNewborn Wistar rat pups (males n=40, females n=40) were treated with aldosterone synthase inhibitor FAD286 (30 mg/kg per day, orally) or vehicle from PND3 to PND9. To verify the pharmacodynamic action of FAD286, serum and adrenal glands from 10-day-old pups were analysed. The remaining pups were weaned on PND21 and underwent open-field (PND23), elevated plus-maze (PND29) and salt-preference testing. At PND46, half of each group was exposed to restraint stress for 120 min. ResultsIn 10-day-old pups, treatment with FAD286 resulted in increased gene expression of CYP11B2 (aldosterone synthase) and CYP11B1 (11-beta-hydroxylase) in the adrenal glands, increased serum levels of corticosterone, and decreased concentrations of serum aldosterone. FAD286 did not modify the general locomotor activity assessed in juvenile rats. Inhibition of aldosterone synthase by FAD286 resulted in altered anxiety-like behaviour in a sex-dependent manner. Postnatal FAD286 treatment led to increased anxiety-like behaviour in female, but not male rats. During adolescence, early FAD286 treatment increased overall aldosterone concentrations without altering the aldosterone response to restraint. Basal corticosterone concentrations were unchanged, whereas the response to restraint was enhanced. ConclusionsThe present study demonstrates that transient inhibition of aldosterone synthesis during the SHRP led to alterations in anxiety-related behaviour and adrenocortical regulation later in development, with some behavioural effects being sex-dependent.

physiology↗

Inhibition of fatty acid amide hydrolase (FAAH) by URB597 counteracts cognitive deficit and alters neuroendocrine stress responses in male and female rats

Cognitive deficits are hallmark features of several neuropsychiatric disorders, yet therapeutic options remain scarce. Modulation of the endocannabinoid system through inhibition of fatty acid amide hydrolase (FAAH) represents a promising target that may influence both cognitive functions and the neuroendocrine system. However, mechanisms linking FAAH inhibition to these outcomes remain poorly understood. In this study, we hypothesised that FAAH inhibition by URB597 counteracts scopolamine-induced memory deficits and modulates neuroendocrine reactivity differently in males and females. We tested the effects of URB597 (0.3 mg/kg, i.p.) in Sprague Dawley rats at baseline and during a scopolamine challenge (0.5 mg/kg, i.p.). Recognition memory was assessed in the novel object recognition (NOR) task, which also served as a mild stressor. Plasma concentrations of adrenocorticotropic hormone (ACTH), corticosterone, vasopressin, aldosterone, and plasma renin activity (PRA) were measured. URB597 pretreatment counteracted the cognitive impairment induced by scopolamine, showing greater efficacy in males. FAAH inhibition reduced ACTH, corticosterone, vasopressin, and aldosterone concentrations, while PRA remained unaffected. Correlation analyses revealed sex-specific associations. In males, better recognition performance was associated with lower ACTH, corticosterone, and vasopressin, whereas in females, cognition correlated negatively with aldosterone and positively with PRA. These findings demonstrate that FAAH inhibition elicits cognitive protection, associated with the attenuation of neuroendocrine stress responses, and this effect is distinct in males and females. By linking behavioural and endocrine outcomes, this study identifies dual actions of FAAH inhibition and underscores the importance of sex as a biological variable in endocannabinoid-based therapeutic strategies.

neuroscience↗